Aspirin might really be a man’s drug First it had been an apple, now it is an aspirin a day time that may keep the doctor away. Aspirin has become standard for coronary attack prevention, but analysis published in the online open gain access to journal BMC Medicine suggests that this may really be considered a man’s drug . Scientists have long puzzled over why the protective effects of aspirin vary therefore widely between medical trials. Some trials display no difference between placebo and aspirin, whilst others record that aspirin decreases the risk of a coronary attack by more than 50 percent.

Quizartinib is definitely well tolerated, with gastrointestinal toxicities becoming the most common and also reversible QT prolongation that was infrequently grade 3, with one case of Quality 4 QT prolongation, at the doses used in this trial. These data claim that quizartinib may become an option for achieving leukemic control for elderly AML sufferers that no longer react, or are refractory, pursuing front-series chemotherapy. For a %age of elderly AML individuals who can tolerate a HSCT, quizartinib may be able to provide a bridge to curative HSCT potentially. Related StoriesPotential new medication target for acute myeloid leukemiaNew study reveals that social factors may impact critical areas of health in AML patientsPenn study forms basis for brand-new treatment approaches for Sezary syndrome BENEFITS of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Research of Quizartinib in Individuals with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Series Chemotherapy or Hematopoietic Stem Cell Transplantation Tag Levis, M.D., Ph.D., Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland Data through Sept.